Regulations.gov document
Exhibit D - NDA 21-303, 8.13.2.6, SLI 381.201 A Randomized Double-Blind, Placebo and…
Supporting & Related Material · FDA-2005-P-0120 · posted Apr 12, 2012
Key facts
| Document ID | FDA-2005-P-0120-0013 |
|---|---|
| Title | Exhibit D - NDA 21-303, 8.13.2.6, SLI 381.201 A Randomized Double-Blind, Placebo and Active Controlled Crossover Study of SLI 381 in Children with Attention Deficit Hyperactivity Disorder re Shire Pharmaceuticals Group - Citizen Petition Part 1 of 2 |
| Document type | Supporting & Related Material |
| Subtype | Citizen Petition |
| Agency | FDA |
| Docket | FDA-2005-P-0120 |
| Posted | Apr 12, 2012 |
| Effective date | Oct 17, 2005 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: